The NASDAQ's recently published "guidelines" (I see them more as requirements) of Board Diversity Rules
https://listingcenter.nasdaq.com/assets/Board...Things.pdf

Quote:

---

4. Smaller Reporting Companies, Foreign Issuers, and companies with five or fewer directors have additional flexibility to meet the diversity objectives.

Smaller Reporting Companies have additional flexibility and can meet the diversity objective with two female directors, or with one female director and one director who is an underrepresented minority or LGBTQ+. Similarly, Foreign Issuers can meet the diversity objective with two female directors, or with one female director and one director who is an underrepresented individual based on national, racial, ethnic, indigenous, cultural, religious or linguistic identity in the country of the company’s principal executive offices, or LGBTQ+. Companies with five or fewer directors can meet the diversity objective by having at least one diverse director.

---

Hmmm....CytoDyn has SIX board seats...but they should fall under "Smaller Reporting Companies" category....at least until things really take off...

The current CytoDyn board will have to make a few changes in the next three years to comply.

The 13D group will need to make even more changes to comply....or someone on the 13D slate isn't giving "full disclosure" on something.....